BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1087 related articles for article (PubMed ID: 20156581)

  • 1. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.
    Mazurek S
    Int J Biochem Cell Biol; 2011 Jul; 43(7):969-80. PubMed ID: 20156581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells.
    Eigenbrodt E; Reinacher M; Scheefers-Borchel U; Scheefers H; Friis R
    Crit Rev Oncog; 1992; 3(1-2):91-115. PubMed ID: 1532331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyruvate kinase type M2: a crossroad in the tumor metabolome.
    Mazurek S; Grimm H; Boschek CB; Vaupel P; Eigenbrodt E
    Br J Nutr; 2002 Jan; 87 Suppl 1():S23-9. PubMed ID: 11895152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tumor metabolome.
    Mazurek S; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):1149-54. PubMed ID: 12820363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply.
    Spoden GA; Rostek U; Lechner S; Mitterberger M; Mazurek S; Zwerschke W
    Exp Cell Res; 2009 Oct; 315(16):2765-74. PubMed ID: 19563799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours.
    Mazurek S
    Ernst Schering Found Symp Proc; 2007; (4):99-124. PubMed ID: 18811055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism.
    Mazurek S; Drexler HC; Troppmair J; Eigenbrodt E; Rapp UR
    Anticancer Res; 2007; 27(6B):3963-71. PubMed ID: 18225557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7.
    Mazurek S; Zwerschke W; Jansen-Dürr P; Eigenbrodt E
    Oncogene; 2001 Oct; 20(47):6891-8. PubMed ID: 11687968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase.
    Mor I; Carlessi R; Ast T; Feinstein E; Kimchi A
    Oncogene; 2012 Feb; 31(6):683-93. PubMed ID: 21725354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells.
    Gumińska M; Ignacak J; Kedryna T; Stachurska MB
    Acta Biochim Pol; 1997; 44(4):711-24. PubMed ID: 9584851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex.
    Mazurek S; Zwerschke W; Jansen-Dürr P; Eigenbrodt E
    Biochem J; 2001 May; 356(Pt 1):247-56. PubMed ID: 11336658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells.
    Tamada M; Suematsu M; Saya H
    Clin Cancer Res; 2012 Oct; 18(20):5554-61. PubMed ID: 23071357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death.
    Steták A; Veress R; Ovádi J; Csermely P; Kéri G; Ullrich A
    Cancer Res; 2007 Feb; 67(4):1602-8. PubMed ID: 17308100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer.
    Chaneton B; Gottlieb E
    Trends Biochem Sci; 2012 Aug; 37(8):309-16. PubMed ID: 22626471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW; Petri E; Bichler KH; Feil G
    Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyruvate kinase M2 and cancer: an updated assessment.
    Iqbal MA; Gupta V; Gopinath P; Mazurek S; Bamezai RN
    FEBS Lett; 2014 Aug; 588(16):2685-92. PubMed ID: 24747424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Warburg effect in 2012.
    Bayley JP; Devilee P
    Curr Opin Oncol; 2012 Jan; 24(1):62-7. PubMed ID: 22123234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase.
    Yacovan A; Ozeri R; Kehat T; Mirilashvili S; Sherman D; Aizikovich A; Shitrit A; Ben-Zeev E; Schutz N; Bohana-Kashtan O; Konson A; Behar V; Becker OM
    Bioorg Med Chem Lett; 2012 Oct; 22(20):6460-8. PubMed ID: 22963766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF.
    Schmidt M; Kammerer U; Segerer S; Cramer A; Kohrenhagen N; Dietl J; Voelker HU
    Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):72-8. PubMed ID: 18394773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.